| Document |
Document Title |
|
WO/2023/241571A1 |
The present invention relates to a compound and a use thereof in synthesis of an immunologic adjuvant KRN7000. The compound is KRN7k-9. A method for synthesizing the immunologic adjuvant KRN7000 comprises: (1) synthesizing a saccharide b...
|
|
WO/2023/239935A1 |
The present disclosure relates to compositions and assays for detecting gastric IF in bodily fluids like blood and urine and use of such compositions and assays in detecting IF-related disease conditions.
|
|
WO/2023/231091A1 |
A single-molecular-weight amphiphilic oligomer having a main chain containing azobenzene and a side chain containing sugar, a preparation method therefor and a use thereof. Hydrophobic main-chain-type azobenzene oligomer precursors havin...
|
|
WO/2023/224108A1 |
Provided is a nucleoside represented by formula (1). [In formula (1): R1 represents a hydroxyl group, a hydroxyl group in which the hydrogen atom is substituted by an alkyl or alkenyl group, or a protected hydroxyl group; R2 represents a...
|
|
WO/2023/220671A1 |
Provided herein is a prodrug compound of Formula I, or a pharmaceutically acceptable salt thereof, as well as compositions comprising the compound. Use of the compound or composition for the treatment of cancer is also provided.
|
|
WO/2023/182317A1 |
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclo...
|
|
WO/2022/183081A9 |
Compounds useful for forming nucleic acids having the structure of Formula (I). Each of R1 or R2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R3 is selected from H, F, O-C1-6 alkyl, O-MOE and a...
|
|
WO/2023/156601A1 |
The present invention relates to radio- and fluorescence-labeled compounds, as well as their use as Diagnostics for Detecting Ecto-5'-Nucleotidase (CD73). The invention is further directed to a pharmaceutical composition comprising said ...
|
|
WO/2023/138099A1 |
The present invention relates to a preparation method for miglitol. Specifically, the method of the present invention comprises: using a compound represented by formula VI as a raw material, subjecting the raw material to sulfonylation a...
|
|
WO/2023/121483A1 |
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...
|
|
WO/2023/109801A1 |
A supramolecular hydrogel capable of lipophilic drug delivery, a preparation method therefor, and a use thereof. The structure of the supramolecular hydrogel is represented by formula I, in which R1 and R2 are independently selected from...
|
|
WO/2023/092892A1 |
Preparation of a DNA-templated gold nanocluster probe having a precise number of atoms, and an application thereof. The preparation comprises: (1) designing a specific DNA sequence having a hairpin structure; (2) mixing a DNA solution wi...
|
|
WO/2023/058608A1 |
Provided are novel glucose derivatives and an anticancer agent using the same. The glucose derivatives according to the present invention consist of an L-glucose derivative represented by general formula (1) and a D-glucose derivative re...
|
|
WO/2023/046875A2 |
A cis-platinum(II)-oligomer hybrid capable of targeting purine-rich targets in genomic DNA, and crosslinking the DNA, is described. The hybrids are generated by conjugating an azide-modified cis-platinum(II) complex with an alkyne-modifi...
|
|
WO/2023/036932A1 |
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According t...
|
|
WO/2023/021286A2 |
The present invention relates to novel nucleotide complexes which enhance the enzymatic production of DNA. The nucleotide complexes includes a divalent cation at a ratio of 0.2-1.5 divalent cations per nucleotide, whilst monovalent ions ...
|
|
WO/2023/279277A1 |
The present application provides a method for preparing an organotin-sucrose complex, comprising: acylating a DMF solution of sucrose with an organotin ester catalyst under predetermined conditions to generate an organotin-sucrose comple...
|
|
WO/2022/255469A1 |
Provided are a novel nucleic acid oligomer and a method for producing the same. The nucleic acid oligomer according to the present invention includes a nucleotide unit represented by general formula (1) and a nucleotide unit represente...
|
|
WO/2022/214692A1 |
A novel pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates are provided. The pseudo solid phase protecting group is represented by formula II wherein: * indicates the poin...
|
|
WO/2022/162656A1 |
A composition including a monovalent copper compound and Porphyridium sp. Polysaccharide (PS). Methods of making the composition are also disclosed.
|
|
WO/2022/103842A1 |
The present disclosure describes novel reagents and processes for preparing oligonucleotides, which have two or more nucleotides. In one embodiment, the reagent is represented by Formula I' or B.
|
|
WO/2022/101588A1 |
The present invention relates to a complex of cationic or neutral gold (I) with fluorinated NHC ligands, as well as the uses thereof as an anti-oxidant, anti-cancer, anti-bacterial and/or anti-parasitic agent and, in particular, an anti-...
|
|
WO/2022/065413A1 |
The present invention addresses the problem of providing a novel artificial nucleic acid, a method for producing the same, and a use thereof. The problem can be solved by an artificial nucleic acid having a unit derived from a compound r...
|
|
WO/2022/017390A1 |
A method for preparing a vitamin B12 crude product, comprising: filtering pseudomonas denitrificans after acidification, hydrolysis, and flocculation sedimentation, and respectively collecting filter residues and a filtrate; leaching the...
|
|
WO/2021/201109A1 |
Provided is an L-glucose derivative represented by general formula (1). [In formula (1), X1 represents a -SAuR1 group, and X2, X3, X4, and X5 each independently represent a -OR2 group, a -NH2 group, or a fluorine atom. R1 represents a li...
|
|
WO/2021/089730A1 |
Biologically active compounds and their methods of preparation are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative disease...
|
|
WO/2021/075423A1 |
The present invention addresses the problem of providing a phosphoramidite activator which improves the solubility of 5-benzylthio-1H-tetrazole in acetonitrile without lowering the yield and purity of a target product. The present inve...
|
|
WO/2021/070507A1 |
A purpose of the present invention is to provide a method for producing a high-purity glycoside compound. The present invention provides a method for producing a glycoside compound of formula (3) (in the formula, Ba, i-Pr, and n are as d...
|
|
WO/2020/236903A1 |
The present disclosure provides pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206. In an aspect, the present disclosure encompasses a pharmaceutical formulation for administration...
|
|
WO/2020/190073A1 |
The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophyl...
|
|
WO/2020/180645A1 |
The present invention is directed to assay methods and compounds and kits used in such assays.
|
|
WO/2020/168283A1 |
The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compou...
|
|
WO/2019/145713A9 |
The present invention relates to methods for the high fidelity synthesis of oligonucleotides and polynucleotides on a solid surface. In particular, the invention relates to methods of synthesising oligonucleotides, polynucleotides, and d...
|
|
WO/2020/158910A1 |
Disclosed are a 5'-modified nucleoside and a nucleotide using the same. The nucleoside according to the present invention is represented by formula (I). The 5'-modified nucleoside according to the present invention is usable as a substit...
|
|
WO/2020/157439A1 |
The invention relates to compounds of formula (I), in which X, Y, L and Ln3+ are as defined in the description.
|
|
WO/2020/073657A1 |
Provided by the present invention are carbohydrate monophosphines represented by general formula Ia, Ib, IIa or IIb, comprising mixtures represented by Ia and Ib having different phosphorus atom configurations, or mixtures represented by...
|
|
WO/2020/014776A1 |
An oral dispersible film composition comprising at least one active ingredient and a film forming agent, as well as a method of manufacture of same. The oral dispersible film composition can be free of gum resin, and can be utilized to a...
|
|
WO/2020/014386A1 |
The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
|
|
WO/2020/001812A1 |
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
|
|
WO/2019/228286A1 |
The invention falls within the field of biomedical technology, and invents a new anti-tumor compound which forms an immune activator cisplatin complex by means of a reaction with a cisplatin drug molecule via an innate immune pathway ago...
|
|
WO/2019/172210A1 |
[Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof
|
|
WO/2019/155639A1 |
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.
|
|
WO/2016/199165A9 |
This invention comprises a method of transmucosal delivery of process of Vitamin B 12 without the need of intrinsic factor comprising administering a solid composition comprising a Vitamin B 12 and at least one bifunctional macromolecule...
|
|
WO/2019/092572A1 |
The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase ...
|
|
WO/2019/088179A1 |
Provided are: a nucleoside that is more suitable for practical use such as an RNA medicine or the like; and the use of the nucleoside. For this purpose, provided is a nucleoside derivative represented by formula (1) or (2) or a salt ther...
|
|
WO/2018/230479A1 |
[Problem] To provide a drug that replaces nucleoside anti-cancer agents or anti-virus agents clinically used as therapeutic medicines for cancer or virus infection, that is highly stable against various hydrolytic metabolic enzymes, that...
|
|
WO/2018/215578A1 |
The present invention concerns a cobalamin derivative of formula (I), wherein X is a ligand having a formula selected from the group consisting of: -(CH2)1-5-S-(CH2)0-3-CH3( -S-(CH2)1-5-NH2 or -S-CH-C-N-H R1 R2 R3 Il wherein R1 = H, meth...
|
|
WO/2018/211392A1 |
A metal contamination detection system, forming part of a cyanide detection system, comprising a solid buffer, the buffer being adapted to provide a pH of from 9-10. The system is especially useful when used in conjunction with a corrino...
|
|
WO/2018/190493A1 |
The present invention relates to a method for synthesizing sucralfate and sucralfate thereby. More specifically, sucralfate is obtained through: a first step for sulfating sucrose to prepare sucrose polysulfate; a second step for neutral...
|
|
WO/2018/189546A1 |
The present invention relates to chemical linkers and protecting groups, compounds and compositions containing the chemical linkers or protecting groups, and intermediates and processes that can be used to prepare them. The chemical link...
|
